* Arris Pharmaceutical Corp., of South San Francisco, has begunU.S. clinical trials of APC 366-A, a small molecule compounddesigned to inhibit the mast cell protease tryptase, for treatment ofasthma. The Phase I studies are the first U.S. clinical trials for thecompany, which also is testing APC 366-A in the U.K.* Carrington Laboratories Inc., of Irving, Texas, has signed acooperative research and development agreement with the NationalKidney Foundation and the U.S. Army to test acemannan hydrogelfor treatment of sunburn. The drug currently is marketed for first andsecond degree burns as well as pressure and stasis ulcers and skinirritations.
(c) 1997 American Health Consultants. All rights reserved.